4.7 Review

Progressive multifocal leukoencephalopathy in HIV-1 infection

期刊

LANCET INFECTIOUS DISEASES
卷 9, 期 10, 页码 625-636

出版社

ELSEVIER SCI LTD
DOI: 10.1016/S1473-3099(09)70226-9

关键词

-

资金

  1. NIH [R01 NS041198 and 047029, K24 NS 060950]
  2. Ministerio de Sanidad y Consumo
  3. Instituto de Salud Carlos III, Madrid (Spain)
  4. Spanish Network for AIDS Research [RD06/006]
  5. Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona (Spain).
  6. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047029, R01NS041198, K24NS060950] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Progressive multifocal leukoencephalopathy is caused by the JC polyomavirus (JCV) and is one of the most feared complications of HIV-1 infection. Unlike other opportunistic infections, this disease can present when CD4 counts are higher than those associated with AIDS and when patients are receiving combined antiretroviral therapy, either shortly after starting or, more rarely, during long term successful treatment. Clinical suspicion of the disease is typically when MRI shows focal neurological deficits and associated demyelinating lesions; however, the identification of JCV in cerebrospinal fluid or brain tissue is needed for a definitive diagnosis. Although no specific treatment exists, the reversal of immumosuppression by combined antiretroviral therapy leads to clinical and MRI stabilisation in 50-60% of patients with the disease, and JCV clearance from cerebrospinal fluid. A substantial proportion of patients treated with combined antiretroviral therapy develop inflammatory lesions, which can be associated with either a favourable outcome or clinical worsening. The reasons for variability in the natural history of progressive multifocal leukoencephalopathy and treatment responses are largely undefined, and more specific and rational approaches to management are needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据